# DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

> **NCT00005091** · PHASE2 · COMPLETED · sponsor: **Daiichi Pharmaceuticals**

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** exatecan mesylate

## Key facts

- **NCT ID:** NCT00005091
- **Lead sponsor:** Daiichi Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-02
- **Primary completion:** —
- **Final completion:** 2003-08
- **Target enrollment:** — (—)
- **Last updated:** 2013-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005091, "DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00005091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*